Gilead Sciences: Don’t Expect Perfection

As if Gilead Sciences ( GILD ) didn't have enough to worry about with competition in hepatitis C , now the Wall Street Journal is reporting that GlaxoSmithKline ( GSK ) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.